Abstract
Coffee silverskin (CS) is the major by-product of coffee roasting and a source of caffeine and chlorogenic acids (CGA), recognized modulators of sugar metabolism. In this work, the effect of a CS extract on glucose and fructose uptake by human intestinal epithelial (Caco-2) cells was ascertained. Freeze-dried aqueous extracts were prepared using an ultrasound probe. The obtained powder was characterized regarding its caffeine content and CGA profile by RP-HPLC-DAD. Caco-2 cells were incubated (at 37 °C for 24 h) with 1 mg/mL of extract, and then glucose and fructose uptake were measured by incubating the cells (at 37 °C for 6 min) with 10 nM 3H-deoxy-D-glucose (3H-DG) or 100 nM 14C-fructose (14C-FRU), respectively. The effects of the major compounds identified were similarly assessed using standards, individually and combined. Furthermore, the mRNA levels of the intestinal transporters of these sugars (SGLT1, GLUT2, and GLUT5) were quantified by RT-qPCR after cell treatment (for 24 h) with the CS extract. Caffeine was the main component of the extract and 5-caffeoylquinic acid (5-CQA) was the major CGA, followed by 5-feruloylquinic acid (5-FQA). Other isomers were found in minor amounts (3-CQA, 4-CQA, and 4-FQA). CS was able to significantly reduce 3H-DG and 14C-FRU uptake (~17% and ~19%, respectively). These effects were not related to cytotoxicity, as confirmed by the lactate dehydrogenase assay. When testing individual compounds at the concentrations present in the extract, neither caffeine nor 5-CQA influenced 3H-DG and 14C-FRU uptake, but significant inhibitions were found when the compounds were combined together (~16% and ~18%, for 3H-DG and 14C-FRU uptake, respectively). This synergistic activity suggests their major role in CS effects. The extract also decreased (in 71%) the expression levels of the GLUT2 transporter, without any influence on the SGLT1 and GLUT5 transporters, thus evidencing the importance of GLUT2 on sugar uptake results. Overall, these findings highlight the beneficial effects that CS might have on type 2 diabetes and other metabolic disorders.
Author Contributions
Conceptualization, J.A.B.P., N.A., F.M. and R.C.A.; methodology, N.A., S.M., A.S.G.C., F.M. and R.C.A.; validation, F.M. and R.C.A.; formal analysis, J.A.B.P., N.A.; investigation, J.A.B.P., N.A., S.M.; resources: R.C.A., M.B.P.P.O. and F.M.; writing—original draft preparation, J.A.B.P. and N.A.; writing—review and editing, M.B.P.P.O., F.M. and R.C.A.; supervision, F.M. and R.C.A.; project administration, R.C.A.; funding acquisition, M.B.P.P.O., F.M. and R.C.A. All authors have read and agreed to the published version of the manuscript.
Funding
This work was supported by the projects funded by FCT/MCTES (Portugal): PTDC/SAU-NUT/2165/2021 (COBY4HEALTH-Can coffee by-products decrease the risk of metabolic syndrome? A comprehensive approach to reduce waste and valorize health benefits); UIDB/50006/2020; and UID/BIM/04293/2013 (to Fátima Martel). The work was also supported by AgriFood XXI I&D&I project (NORTE-01-0145-FEDER-000041) cofinanced by European Regional Development Fund (ERDF) through the NORTE 2020 (Programa Operacional Regional do Norte 2014/2020). N.A. and S.M. are grateful to the project PTDC/SAU-NUT/2165/2021-COBY4HEALTH for their research and post-doc grants, respectively. J.A.B.P. and R.C.A. are grateful to FCT for their PhD grant (SFRH/BD/07329/2021) and CEECIND/01120/2017 contract, respectively.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Not applicable.
Acknowledgments
The authors thank to BICAFÉ for kindly providing the samples for the study.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).